Related Experiment Video
Updated: Jul 15, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species
Jérôme Alexandre1, Yumin Hu, Weiqin Lu
1Department of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77054, USA.
Abstract:
Generation of reactive oxygen species (ROS) has been observed in cancer cells treated with paclitaxel, but the underlying mechanisms and therapeutic implications remain unclear. In the present study, we showed that paclitaxel promoted ROS generation through enhancing the activity of NADPH oxidase (NOX) associated with plasma membranes. Treatment of breast cancer cells caused an increased translocation of Rac1, a positive regulatory protein of NOX, to the membrane fraction. The paclitaxel-induced ROS generation occurred rapidly within several hours of drug exposure, with O(2)(-) and H(2)O(2) accumulation mainly outside the cells while the intracellular ROS remained unchanged. Importantly, the increase in extracellular ROS caused lethal damage to the bystander cancer cells not exposed to paclitaxel, as shown by two different methods using coculture systems where the bystander cells were differentiated from the paclitaxel-treated cells by fluorescent or radioactive labeling. This cytotoxic bystander effect was also observed with other microtubule-targeted agents vincristine and taxotere but not with 5-fluorouracil or doxorubicin. This toxic bystander effect was enhanced by CuZnSOD that converts O(2)(-) to H(2)O(2) and was abolished by a catalase that eliminates H(2)O(2). Furthermore, paclitaxel was able to induce an almost complete inhibition of proliferation of the bystander cells in the coculture system. Our study revealed a novel mechanism by which paclitaxel induces toxic bystander effect through generation of extracellular H(2)O(2) from the membrane-associated NOX. This may contribute to the potent anticancer activity of paclitaxel and provide a novel basis to improve the clinical use of this important drug.
Insights
Paclitaxel generates extracellular reactive oxygen species (ROS) via NADPH oxidase, causing lethal damage to nearby cancer cells. This novel bystander effect enhances paclitaxel
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Paclitaxel induces reactive oxygen species (ROS) in cancer cells, but mechanisms and implications are unclear.
- Extracellular ROS generation by paclitaxel has not been previously characterized.
Purpose of the Study:
- To elucidate the mechanism of paclitaxel-induced ROS generation.
- To investigate the therapeutic implications of paclitaxel-induced extracellular ROS.
- To determine if paclitaxel induces a cytotoxic bystander effect.
Main Methods:
- Investigated paclitaxel's effect on NADPH oxidase (NOX) activity and Rac1 translocation in breast cancer cells.
- Quantified extracellular and intracellular ROS (O2(-) and H2O2) using fluorescent and radioactive labeling in coculture systems.
- Assessed the role of superoxide dismutase (SOD) and catalase in mediating the bystander effect.
- Evaluated the impact of paclitaxel on bystander cell proliferation.
Main Results:
- Paclitaxel rapidly enhanced plasma membrane-associated NOX activity, increasing extracellular O2(-) and H2O2.
- Rac1 translocation to the plasma membrane was increased by paclitaxel treatment.
- Extracellular ROS generated by paclitaxel induced lethal damage and inhibited proliferation in bystander cancer cells.
- This cytotoxic bystander effect was observed with other microtubule-targeting agents but not with 5-fluorouracil or doxorubicin.
Conclusions:
- Paclitaxel induces a novel cytotoxic bystander effect through extracellular ROS generated by membrane-associated NOX.
- This mechanism contributes to paclitaxel's anticancer activity and suggests new therapeutic strategies.
Related Concept Videos
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

